3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
5
Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
HER2-positive Breast Cancer
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Patient Preference
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
Inflammatory Breast Neoplasms
1
Interventions
pembrolizumab
244
Carboplatin
213
Pemetrexed
179
Cisplatin
133
Paclitaxel
115
Nivolumab
102
Docetaxel
88
osimertinib
84
durvalumab
79
Specimen Handling
56
atezolizumab
55
Gemcitabine
53
Drug Therapy
53
Magnetic Resonance Spectroscopy
50
Radiosurgery
49
Radiotherapy
48
Ipilimumab
41
130-nm albumin-bound paclitaxel
39
cemiplimab
38
Bevacizumab
35
tislelizumab
31
Cetuximab
30
amivantamab
23
Taxes
22
Blood Specimen Collection
21
Platinum Compounds
20
Immunotherapy
18
Immune Checkpoint Inhibitors
18
Radiation
17
Erlotinib Hydrochloride
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Ado-Trastuzumab Emtansine
×
1 year
×
Clear all
NCT02314481
2026-05-04
DARWINII
University College, London
Phase 2
Completed
50 enrolled
NCT05650879
2025-07-15
HER2
Enliven Therapeutics
Phase 1
Active not recruiting
198 enrolled